Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen - LARVOL DELTA

LONG-TERM EFFICACY AND SAFETY OF TEZEPELUMAB OVER 52 WEEKS IN ADULTS AND ADOLESCENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE PHASE 3 CROSSING STUDY (UEGW 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

Immunopathogenic Endotypes of Asthma: From Type 2 and Non-Type 2 Inflammation to Precision Therapeutic Strategies. (PubMed, J Asthma) - "Depending on type of inflammation, eosinophilic (anti-IL-5 (mepolizumab) and mixed inflammation (dupilumab/tezepelumab) and high IgE (omalizumab) biomarkers are pivotal in stratifying phenotypes, predicting exacerbation, and informing targeted biologics, including anti-IL-5 (mepolizumab) and dupilumab/tezepelumab, respectively. This synthesis heralds a paradigm shift of empirical symptom control to personalized interventions, reduction of exacerbations, lessening of overtreatment, and the identification of new targets in multi-omics era to overcome the unmet needs of severe, steroid-resistant asthma."

Journal • Review • Allergy • Asthma • Immunology • Inflammation • Oncology • Pulmonary Disease • Respiratory Diseases • IL33 • IL4 • IL5

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies. (PubMed, Eur J Clin Invest) - "COPD management is evolving toward precision medicine, guided by inflammatory phenotypes, biomarkers, and individualised risk profiles. Continued investigation into targeted biologics, anti-inflammatory agents, and incorporating biomarkers into clinical practice may improve outcomes and reduce disease burden."

Biomarker • Journal • Review • Cardiovascular • Chronic Obstructive Pulmonary Disease • Cognitive Disorders • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL33

Influence of newly initiated biologic therapy on the dose of ICS therapy - Data from the German Asthma Net. (PubMed, J Allergy Clin Immunol Pract) - "ICS reduction was associated with improved patient-reported outcomes without worsening exacerbations, lung function or FeNO."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Tezepelumab effectiveness in Aspirin-Exacerbated Respiratory Disease: a real-world multicenter study. (PubMed, Respir Med) - "Tezepelumab was associated with clinically meaningful improvements in patients with severe asthma and AERD. Although patients with AERD showed a trend toward greater clinical benefit than those without AERD, the sensitivity analyses precluded definitive conclusions regarding a differential treatment effect. These findings support further prospective studies to clarify whether AERD identifies a phenotype with enhanced responsiveness to upstream TSLP blockade."

Clinical • Journal • Real-world evidence • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • TSLP

Real-world effectiveness of T2-targeted biologics in patients with chronic obstructive pulmonary disease (COPD) (ERS 2026) - " This retrospective, monocentric study at Foch Hospital included COPD patientstreated for ≥ 3 months with Th2-targeted biologics (benralizumab, dupilumab, mepolizumab,omalizumab, or tezepelumab) between 2018 and 2025. T2-targeted biologics significantly reduce exacerbation frequency and OCS usein COPD patients, regardless of an associated asthma phenotype."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Pulmonary Disease • Respiratory Diseases

Beyond Type 2 Inflammation: How Obesity Impacts Clinical Remission in Biologic-Treated Severe Asthma (ERS 2026) - " Eighty-two SA patients prospectively enrolled and treated with biologics were included (benralizumab n=29, 35.4%; dupilumab n=30, 36.6%; mepolizumab n=16, 19.5%; tezepelumab n=7, 8.5%). Higher baseline BMI was associated with a reduced likelihood of clinical remission in biologic-treated SA, despite comparable modulation of T2 biomarkers, suggesting the involvement of non-T2 mechanisms."

Clinical • Asthma • Genetic Disorders • Immunology • Inflammation • Obesity • Respiratory Diseases

In-clinic and at-home administration of injectable biologics for severe asthma and CRSwNP places a considerable time burden on patients and HCPs: Pooled results from a time and motion study (ERS 2026) - "A time model included dosing frequency (dupilumab [Q2W], mepolizumab [Q4W], omalizumab [Q4W], tezepelumab [Q4W] and benralizumab [Q8W]). Injectable biologic administration was associated with considerable HCP and patient time, with higher dosing frequency driving greater in-clinic administration burden. Funding: GSK (214575)"

Clinical • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Respiratory Diseases

Blocking the IL4/IL-13 pathway improves airway resistance in severe asthma in real-life (ERS 2026) - " This retrospective analysis included 86 patients suffering from severe asthma initiated with different biologicals (Dupilumab (N=34), Tezepelumab (N=21), Mepolizumab (N=18), Benralizumab (N=8) and Omalizumab (N=5)) at the University of Liège, Belgium. Our study shows a significant improvement in airway resistances in both large and small airways in patients receiving Dupilumab for 6 months. The absence of impact of Dupilumab on other IOS measures and the absence of significant changes with other targeted treatments have to be confirmed in larger cohorts."

Clinical • Asthma • Immunology • Respiratory Diseases • IL13 • IL4

TEZEPELUMAB VS DUPILUMAB FOR SEVERE ASTHMA: REAL-WORLD COMPARATIVE EFFECTIVENESS IN REDUCING EXACERBATIONS AND CORTICOSTEROID USE (CHEST 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

Methodological Considerations in the Indirect Comparison of Dupilumab and Tezepelumab. (PubMed, J Allergy Clin Immunol Pract) - No abstract available

Journal

Outcomes of biologic therapy in one hundred Latvian patients with severe asthma: two-year analysis from the SHARP database (ERS 2026) - "43 patients were treated with mepolizumab, 38 with benralizumab, 11 with tezepelumab and 8 with dupilumab. Median ACT score increased from 12 (IQR 10–15) at baseline to 19 (IQR 16–20) at first follow-up and to 18 (IQR 14–21) at second follow-up, reflecting substantial improvement in asthma control (p<0.000001). Two-year treatment with biological therapy resulted not only in a dramatic reduction in exacerbation rate and oral corticosteroid use but also in a clinically significant improvement in lung function and asthma control."

Clinical • Asthma • Immunology • Respiratory Diseases

Dose tapering and treatment de-escalation of biologic therapies in chronic rhinosinusitis with nasal polyps: a narrative review. (PubMed, Front Surg) - "Although dupilumab, omalizumab, mepolizumab, benralizumab, tezepelumab, depemokimab, and stapokibart have demonstrated substantial clinical efficacy, the optimal duration and maintenance strategy for biologic therapy remain uncertain...However, standardized tapering protocols and high-quality randomized controlled trials are required before routine implementation. Future research should focus on biomarker-guided patient selection, long-term clinical outcomes, and the cost-effectiveness of biologic dose optimization."

Journal • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

Clinical effects of biological therapy in allergic bronchopulmonary mycosis (ERS 2026) - "Twenty-two patients that did not respond well to conventional therapy were treated in the biologics group (BG); last biologic; benralizumab in 8, tezepelumab in 7, and dupilumab in 7. Biologics contributed to suppression of asthma and ABPM exacerbations, but improved lung function was evident only during the early phase of treatment."

Clinical • Asthma • Dermatology • Immunology • Infectious Disease • Respiratory Diseases

Association Between Biologic Therapy and Ocular Adverse Events in Chronic Rhinosinusitis with Nasal Polyps (AAO-HNSF 2026) - "Biologics included dupilumab, omalizumab, mepolizumab, benralizumab, tezepelumab, and depemokimab. Biologic therapy for CRSwNP was associated with increased risk of conjunctivitis, glaucoma, keratitis, and blurred vision, with a borderline increase in ocular irritation, while blepharitis and eyelid rosacea were not significant. These findings support counseling and symptom monitoring, and highlight the need for further mechanistic study and drug-specific risk stratification."

Adverse events • Chronic Rhinosinusitis With Nasal Polyps • Conjunctivitis • Dry Eye Disease • Glaucoma • Immunology • Keratitis • Nasal Polyps • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology • Respiratory Diseases • Rosacea • Sinusitis

T2 biomarkers in pediatric severe asthmatic children starting a biologic in the Severe Paediatric Asthma Collaborative in Europe (SPACE) registry, an ERS Clinical Research Collaboration (ERS 2026) - " complete data on BM were available in 143 of the 240 patients included (males: 57%), starting Dupilumab (N=68), Omalizumab, (N=42), Mepolizumab (N=19), Tezepelumab (N=14). pediatric SA qualifying for biologic is characterized by multiple high T2 BM, more so in adolescents. Consequently, patients are eligible to more than one biologic. Choice should be driven by other characteristics or more accurate BM."

Biomarker • Clinical • Asthma • Immunology • Pediatrics • Respiratory Diseases

Biologics Improve Mucus Plugs and Oscillometry-Defined Small Airway Dysfunction in Real-Life Severe Asthma (ERS 2026) - "After a median treatment duration of 9.5 months with mepolizumab (5), benralizumab (8), dupilumab (3), or tezepelumab (4), the median mucus plug score significantly decreased from 2.0 to 0.5. Biologics improved mucus plugs and oscillometry-defined SAD in real-life patients with severe asthma."

Clinical • Asthma • Immunology • Respiratory Diseases

TSLP and IL-4Rα expression in the peripheral lung of stable COPD and controls (ERS 2026) - "Dupilumab and tezepelumab are mAbs, blocking IL-4Rα and TSLP respectively, on the market and/or in clinical trials for stable COPD patients. The number of TSLP and IL-4Rα positive cells was not significantly different in patients with COPD compared to controls, as well as the mRNAs expression for these molecules. TSLP and IL-4Rα protein and mRNA expression are not significantly different in patients with COPD compared to controls."

IO biomarker • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases • TSLP

SAFETY OUTCOMES OF TEZEPELUMAB VS DUPILUMAB IN ADULTS WITH ASTHMA: A PROPENSITY-MATCHED REAL-WORLD ANALYSIS (CHEST 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Asthma • Immunology • Respiratory Diseases

Blood eosinophil subtypes as predictors of response to biologics in severe asthma. (ERS 2026) - " Nineteen patients were included (median age 60 yrs; 67% female): 7 started dupilumab, 7 tezepelumab, 3 benralizumab and 2 mepolizumab. Baseline blood iEos% is associated with functional improvement after 6 months of biologic therapy in SA, but not with exacerbations and symptom improvement. These exploratory findings require confirmation in larger cohorts."

Asthma • Immunology • Respiratory Diseases • SIGLEC8

Efficacy and Predictors of Response to Biologic Therapy and Endoscopic Sinus Surgery in Patients With Nasal Polyps: A Systematic Review. (PubMed, Int Forum Allergy Rhinol) - "ESS and biologics provide clinically meaningful benefit. Among biologics, dupilumab and tezepelumab demonstrated the largest effect sizes, though cross-trial differences in baseline severity, follow-up, and comparators limit indirect comparisons. Head-to-head trials and standardized subgroup analyses are needed to guide treatment selection."

Journal • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

An Unanchored Matching-Adjusted Indirect Comparison of Dupilumab and Tezepelumab in Asthma Has Several Limitations. (PubMed, J Allergy Clin Immunol Pract) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

BBT002, a tetravalent bispecific antibody targeting human IL-4Rα and IL-5, demonstrated enhanced efficacy over single-pathway targeting antibodies in an ovalbumin (OVA)-induced asthma mouse model (ERS 2026) - " An OVA-induced asthma model using hIL4/hIL4Rα/hTSLP/hTSLPR or hIL4/hIL4Rα mice was utilized to evaluate BBT002's efficacy in comparison to dupilumab, a tezepelumab analogue or an anti-IL-5 mAb. These findings indicate that BBT002 may offer broader and more potent anti-T2-inflammatory and disease-alleviating effects than mAbs targeting a single cytokine or alarmins, supporting BBT002 as a differentiated therapeutic."

Bispecific • Preclinical • Asthma • Immunology • Inflammation • Pneumonia • Respiratory Diseases • IL33 • IL4 • IL5 • TSLP

Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review. (PubMed, Int J Chron Obstruct Pulmon Dis) - "Sixteen publications were included, covering 12 studies of seven biologics (astegolimab, benralizumab, dupilumab, itepekimab, mepolizumab, tezepelumab and tozorakimab). Improvements in SGRQ total score were observed in patients with BEC ≥300 cells/µL (dupilumab and tezepelumab) and astegolimab improved SGRQ-C total score in patients with BEC >170 cells/µL. Overall, AECOPD reductions and improvements in lung function and health-related quality of life in patients with moderate to very severe COPD varied by biologic and baseline BEC subgroup; within studies, efficacy was generally greater in patients with an elevated baseline BEC, suggesting these patients may benefit most from biologic treatment."

Journal • Review • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparative real-world effectiveness of benralizumab, mepolizumab, dupilumab and tezepelumab in asthma: a 12-month single-center study (ERS 2026) - "Conclusions In this real-world comparative cohort, all four biologics produced clinically meaningful improvements in asthma control, lung function and exacerbation burden at 12 months. Differences in magnitude of response across agents highlight heterogeneity of treatment effect and support personalised biologic selection in severe asthma."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Asthma • Immunology • Inflammation • Respiratory Diseases